AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Cyber decacorn Wiz in advanced negotiation to acquire Lacework for $150-200 million
2
Israeli Billionaire Hires Black Cube to Spy on Former Partner Company Vale
3
Google employees arrested following protest over Israel ties at executive’s office
4
The price of failure: Dutch company's chip monopoly born from a bad bet by Intel
5
Cyber unicorn Armis acquiring Silk Security for $150 million
More news

Mylan

17 stories about Mylan
מפעל תרופות טבע

Credit Line and Bonds: Teva's Financial Catch

12.08.19|Uri Tal-Tene
At first glance, Teva’s second quarter reports provided little cause for drama. The small print reveals a very different story
נסיעת בכורה של רכבת מהירה מ ירושלים ל תל אביב

Copaxone-Competitor Developer Mapi Pharma Gets Funding for Jerusalem Plant

19.03.19|Lilach Baumer
The clinical-stage company develops more efficient versions of existing successful drugs, including a long-acting version of Teva's multiple sclerosis cash cow
תרופה מזרק אפיפן מיילן אלרגיה

Teva, Mylan Drop on Announcement of Epinephrine Injector Rival

09.12.18|Lilach Baumer
Novartis’ U.S. division Sandoz announced a planned release for early 2019. The company will sell its drug, which lacks the EpiPen’s auto-injector, for $250 a pair out of pocket, compared to Mylan and Teva’s $300
תלמידים כיתה בית ספר לימודים ילדים

Teva’s EpiPen Won’t Hit U.S. Market in Time for School Year, Report Says

26.08.18|Dror Reich
The Israeli drugmaker received approval for a first generic version of Mylan’s auto-injector earlier this month
מטה טבע פתח תקווה

Teva Wins FDA Approval for First Generic EpiPen

19.08.18|Lilach Baumer
EpiPens were sold for less than $60 when Mylan acquired the injectors in 2007. Market Monopoly enabled the company to hike its price up to around $300 a unit today
אלרגן משרדים

Court Rules Allergan Can't Use Indian Tribe Deal to Protect Patents

23.07.18|CTech
In September 2017, Allergan transferred six of its patents for blockbuster dry eye drug Restasis to the St. Regis Mohawk Tribe, hoping to protect the patents under the principle of sovereign immunity
ה מטה הנוכחי של טבע ב ארה"ב

Mylan Cuts Price of Generic Copaxone Offering by 60%

11.07.18|Lilach Baumer
Mylan has achieved a 15%-20% market share in the U.S. since launching its generic version in late 2017 with a monthly price tag of $5,000, compared to Teva's $5,800
עובדי טבע פתח תקווה מפגינים על ציר ז'בוטינסקי

CTech’s Daily Israeli Tech News Roundup

17.12.17|CTech
Teva might have been better off as a smaller company, new CEO says. Tel Aviv airport, stock market open as in support of Teva employees ends. A new blockchain powered juggernaut stock arrives on the Tel Aviv Stock Exchange
אורי טל טנא פרשן שוק ההון

Teva Wants to Be Like Mylan: Agile, Lean and Profitable

17.12.17|Uri Tal-Tenne
The cost-cutting plan revealed Thursday by Teva CEO Kåre Schultz showcases an intention to transform Teva into a lean and efficient generic drug company, much like main competitor Mylan
לוגו ctech

CTech’s Daily Israeli Tech News Roundup

26.11.17|CTech
Amazon plans to set up a shipping center in Israel. Israeli parliamentarian criticizes Israeli arms export policy.
מפעל טבע הר חוצבים ירושלים

Mylan's Chairman was Right

26.11.17|Sophie Shulman
In a 2015 letter, Robert J. Coury forecasted Teva’s current troubles
ראג'יב מאליק נשיא מיילן

Investors Cheer as Mylan Plans to Delist from Israeli Stock Exchange

12.11.17|Uri Tal-Tenne and Dror Reich
Mylan is currently the highest valued company on the TASE at $18.5 billion
קור שולץ מנכ"ל טבע החדש

With New CEO in Seat, Teva Lowers Outlook

02.11.17|Lilach Baumer and Dror Reich
Outlook reflects an earlier than expected launch of a generic competitor to Teva’s multiple sclerosis drug Copaxone
מפעל חברת טבע הר חוצבים ירושלים

Teva's Blockbuster Drug Takes Another Generic Blow

26.10.17|Lilach Baumer
Mylan and European Partner Synthon won U.K. patent case related to Teva's Copaxone
default image

Teva Loses Copaxone Market Exclusivity

04.10.17|Lilach Baumer
Rival Mylan received FDA approval for its generic versions of Copaxone, Teva’s flagship drug
Cummings Welch

U.S. Congress to Investigate Rising Multiple Sclerosis Drug Prices

21.08.17|Dror Reich
Two Congressmen are looking into the rising MS drug prices of seven pharmaceutical companies
תרופות טבע גלולות תרופה

With Bloated Debt, Teva Looks to Sell Assets

10.08.17|Eli Shimony and Gil Kalian
The generic drugmaker said it is looking to sell Medis, an Iceland-based company it bought in 2016